Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript

Page 3 of 3

John Butler: Thanks, Andrew. And I just want to make one correction. I referenced 12 years of exclusivity and my crack team already got back to me and said it’s 10 years exclusivity in Europe. So thank you. Thanks for that. But a very nice opportunity for our partner and for Akebia. So I do want to thank everyone for joining us this morning. Our organization is excited, focused and executing on the opportunities ahead of us. Since our last earnings report, we’ve received approval for Vafseo. We’re engaging thousands of potential prescribers. We’ve had contracting discussions for both of our products with almost all significant dialysis providers. We’ll submit our application for TDAPA reimbursement in June. We’re finalizing plans for a significant collaborative research study with Vafseo.

We’ve simplified our working capital fund repayment with Vifor CSL. We’re preparing to engage FDA on a path for the new dialysis and the pre-dialysis patient populations. We’re supporting one partner for a launch of Vafseo in Europe this quarter, and a second on a potential launch of Auryxia in Europe next year. And we’re doing all of this from a position of financial strength. I look forward to continuing to update you on our progress. Have a great day.

Operator: Ladies and gentlemen, thank you for participating. This does conclude today’s program and you may now disconnect.

Follow Akebia Therapeutics Inc. (NASDAQ:AKBA)

Page 3 of 3